Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.56 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29687690 | 1.00 | ANPEP (0.56) | ANPEPSLC18A3IDO1SIGMAR1PLAU | |
| SCHEMBL20095994 | 1.00 | ANPEP (0.56) | ANPEPSLC18A3IDO1SIGMAR1PLAU | |
| SCHEMBL1990446 | 1.00 | ANPEP (0.56) | ANPEPSLC18A3IDO1SIGMAR1PLAU | |
| SCHEMBL1990443 | 1.00 | ANPEP (0.56) | ANPEPSLC18A3IDO1SIGMAR1PLAU | |
| Naphthalene SCHEMBL8201172 | 0.92 | ANPEP (0.50) | ANPEPSLC18A3IDO1SIGMAR1 | |
| SCHEMBL6932695 | 0.82 | ANPEP (0.47) | ANPEPSLC18A3IDO1SIGMAR1 | |
| SCHEMBL11355392 | 0.82 | ANPEP (0.68) | ANPEPSLC18A3IDO1PLAU | |
| SCHEMBL22893170 | 0.82 | ANPEP (0.47) | ANPEPSLC18A3IDO1SIGMAR1 | |
| SCHEMBL3996873 | 0.82 | ANPEP (0.68) | ANPEPSLC18A3IDO1PLAU | |
| SCHEMBL9515317 | 0.82 | ANPEP (0.68) | ANPEPSLC18A3IDO1PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | ANPEP 1983/4885SLC18A3 2528/4885IDO1 2327/4885 |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | NPY5R, REN, F12 | ANPEP 1983/4885SLC18A3 2528/4885IDO1 2327/4885 |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | ANPEP 1906/4885SLC18A3 2402/4885IDO1 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.